(HealthDay)—Discontinuation of acetylcholinesterase inhibitors (AChEIs) for treatment of Alzheimer’s disease is common, with adverse effects and cost cited as major factors, according to a study published recently in the Journal of the American Geriatrics Society.
from Dementia Big http://ift.tt/2oK7PKq via alcoholic dementia
http://ift.tt/2oxwt5Y
No comments:
Post a Comment